Genetic variants of N-acetyltransferases 1 and 2 (NAT1 and NAT2) in cynomolgus and rhesus macaques
- 25 April 2020
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 177, 113996
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Arylamine N‐acetyltransferases: from drug metabolism and pharmacogenetics to drug discoveryBritish Journal of Pharmacology, 2014
- Arylamine N‐acetyltransferases: a structural perspectiveBritish Journal of Pharmacology, 2013
- N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicineExpert Opinion on Drug Metabolism & Toxicology, 2009
- Structure/Function Evaluations of Single Nucleotide Polymorphisms in Human N-Acetyltransferase 2Current Drug Metabolism, 2008
- Arylamine N-acetyltransferases: From Structure to FunctionDrug Metabolism Reviews, 2008
- Functional Analysis of the Human N-Acetyltransferase 1 Major Promoter: Quantitation of Tissue Expression and Identification of Critical Sequence ElementsDrug Metabolism and Disposition, 2007
- NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analysesThe Lancet, 2005
- ArylamineN-Acetyltransferases: What We Learn from Genes and GenomesDrug Metabolism Reviews, 2005
- Expression of arylamine N -acetyltransferase in human intestineGut, 1998
- Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid.Journal of Clinical Investigation, 1965